Liquid Biopsy Market Size To Reach $22.88 Billion By 2030

May 2025 | Report Format: Electronic (PDF)

Liquid Biopsy Market Growth & Trends

The global liquid biopsy market size is expected to reach USD 22.88 billion by 2030, registering a CAGR of 11.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer and the growing geriatric population are major drivers expected to fuel market growth. Furthermore, the use of technologically advanced devices for early detection of diseases is one of the key factors driving the market. In addition, the increasing preference for noninvasive treatment procedures will offer lucrative opportunities in the forecast period.

In recent years, cases of cancer have been rising tremendously and the trend is projected to remain the same in the foreseeable future. A significant shift in lifestyle has exposed the global population to this disorder and has resulted in oncogenic factors. For instance, as per the American Cancer Society, in 2022, the number of new cancer cases is expected to reach 1.9 million, leading to 609,360 deaths. Companies are focusing on expanding their business operations in the clinical liquid biopsy space.

For instance, in December 2021, Helio Health and Fulgent Genetics announced the launch of the former’s HelioLiver, a new liquid biopsy test for early liver cancer detection. This liquid biopsy test combines serum protein markers and cell-free DNA methylation patterns. Additionally, new research studies are aiding the development of novel liquid biopsy techniques. For instance, in July 2022, the University of Central Florida announced the development of a novel liquid biopsy technique that facilitates early detection using biomarker identification for lung and breast cancer, making the monitoring of conditions easier.

The enhanced interest of players in liquid biopsy and the increasing rate of approval of new products are further accelerating market growth. Moreover, in the past several years, studies have shown a positive outcome of liquid biopsy platforms. Governments and various regulatory bodies have also shown interest in the area by promoting multiple breakthrough devices for the rapid development of this technology. With the high adoption of the technology by various companies, along with the support of government funding and initiatives, the market is expected to grow in the coming years.

key Request a free sample copy or view report summary: Liquid Biopsy Market Report

Liquid Biopsy Market Report Highlights

Based on technology, the multi-gene-parallel analysis (NGS) segment led the market with the largest revenue share of 76.17% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period.
Based on biomarker, the circulating tumor cells (CTC) biomarker segment led the market with the largest revenue share of 35.67% in 2024. The exosomes/microvesicles segment is anticipated to grow at the fastest CAGR of 13.82% over the forecast period.
Based on application, the cancer segment led the market with the largest revenue share of 86.31% in 2024. The reproductive health segment is anticipated to grow at the fastest CAGR of 12.75% over the forecast period.
Based on end use, the hospitals and laboratories segment led the market with the largest revenue share of 42.44% in 2024. The specialty clinics segment is anticipated to grow at the fastest CAGR of 12.16% over the forecast period.
Based on clinical application, the therapy selection segment led the market with the largest revenue share of 33.69% in 2024. The early screening segment is expected to grow at the fastest CAGR of 12.38% over the forecast period.
The instruments product segment dominated the market with the largest revenue share of 46.74% in 2024. The kits and reagents product segment is expected to grow at a significant CAGR during the forecast period.
Based on sample type, the blood sample segment led the market with the largest revenue share of 71.44% in 2024 and is projected to maintain its dominance over the forecast period.
North America dominated the liquid biopsy market with the largest revenue share of 51.15% in 2024. The liquid biopsy market in Asia Pacific is expected to grow at the fastest CAGR of 13.02% over the forecast period.

Liquid Biopsy Market Segmentation

Grand View Research has segmented The global liquid biopsy market report based on sample type, biomarker, technology, application, end-use, clinical application, product, and region:

Liquid Biopsy Sample Type Outlook (Revenue, USD Billion, 2018 - 2030)